A few weeks ago, McDermott + Bull Interim Leaders and I hosted a small breakfast for C-Level executives in the life sciences sector. Simon Arkell, CEO and Co-Founder of Ryght AI, joined us as our keynote speaker to share his thoughts and insights on AI and its impact...
Recently, my colleague Mark McConnell and I hosted a breakfast meeting with around 40 local C-Suite executives within the life sciences sector. Paul LaViollette, Managing Partner and Chief Operating Officer of SV Health Investors, joined us from Boston to share his...
Earlier this year, the McDermott + Bull Technology and Life Sciences Practice began a search for a client in the life sciences and medical device sector. This client, based in the Southeastern U.S., is a privately held company committed to saving lives and improving...
Volatile. Uncertain. Complex. Ambiguous. VUCA – what was once a nebulous term used to forecast an uncertain future, today is our “new normal.” For the most part, the world has moved past COVID, and when we emerged from the other side, we somewhat expected it to...
In 2022, we saw a significant increase in the number of deals by private equity and venture capital firms within the life sciences, medical, and healthcare sectors. This all points toward positive growth, but the biggest challenge PE and VC firms face is seeing a...
2022 has been an interesting year for life sciences and executive search. We have finally been able to attend in-person conferences and events without the looming fear of the COVID-19 pandemic hanging over our heads. In October, Jessica Combs and I attended the...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy policyOkNo
